| P2093 | author name string | Francis G Spinale | |
| | Rachael Deardorff | |
| P2860 | cites work | Interleukin-10 and the interleukin-10 receptor | Q24290912 |
| | Matrix metalloproteinases | Q28140451 |
| | Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis | Q31121727 |
| | Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay | Q32059280 |
| | Increased circulating cytokines in patients with myocarditis and cardiomyopathy | Q33614427 |
| | Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications | Q33692926 |
| | Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction | Q34138706 |
| | Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation | Q34665150 |
| | Cytokine-induced modulation of cardiac function | Q35980361 |
| | Diastolic heart failure: definitions and terminology | Q36186610 |
| | Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure | Q73825453 |
| | IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury | Q74183226 |
| | Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor | Q74364510 |
| | Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy | Q74588037 |
| | Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy | Q74595368 |
| | Differential expression of tissue inhibitors of metalloproteinases in the failing human heart | Q77465345 |
| | Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes | Q78290470 |
| | How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH | Q78482942 |
| | Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle | Q80055213 |
| | Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution | Q80087614 |
| | Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling | Q80148227 |
| | Prolonged activation of tumor necrosis factor (TNF)-alpha and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3 | Q80998978 |
| | Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure | Q81229994 |
| | C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes | Q81379653 |
| | Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy | Q81586732 |
| | Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease | Q83195156 |
| | Cytokines and cardiovascular disease | Q36188431 |
| | Biomarkers for diagnosing and monitoring autoimmune diseases | Q36318003 |
| | Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function | Q36967674 |
| | Cytokines and myocardial dysfunction: state of the art. | Q37069756 |
| | Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction | Q37083030 |
| | Tumor necrosis factor-alpha and mortality in heart failure: a community study | Q37192858 |
| | Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death | Q37362206 |
| | Interleukin-10 induced activating transcription factor 3 transcriptional suppression of matrix metalloproteinase-2 gene expression in human prostate CPTX-1532 Cells. | Q38338402 |
| | Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure | Q40870003 |
| | Proteinases and myocardial extracellular matrix turnover | Q41377034 |
| | Tumor necrosis factor in the heart. | Q41733185 |
| | Interleukin-6 released from fibroblasts is essential for up-regulation of matrix metalloproteinase-1 expression by U937 macrophages in coculture: cross-talking between fibroblasts and U937 macrophages exposed to high glucose | Q42058025 |
| | Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy | Q42442672 |
| | Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). | Q43586296 |
| | Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function | Q44319404 |
| | Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure | Q44514122 |
| | Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes | Q44523741 |
| | Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study | Q44799903 |
| | Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1beta | Q44989718 |
| | Inflammatory mediators in Chinese patients with congestive heart failure. | Q46034422 |
| | Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality | Q46699519 |
| | Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors | Q46727850 |
| | Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes | Q46731184 |
| | Matrix metalloproteinase-1 and -2 levels are differently regulated in acute exacerbation of heart failure in patients with and without left ventricular systolic dysfunction | Q47732973 |
| | Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction | Q47842313 |
| | Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). | Q47945239 |
| | Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? | Q48006505 |
| | Inflammatory pathways in patients with heart failure and preserved ejection fraction | Q48093168 |
| | Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure | Q48482082 |
| | Blockade of NF-kappaB improves cardiac function and survival without affecting inflammation in TNF-alpha-induced cardiomyopathy. | Q51455210 |
| | Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody. | Q52846337 |
| | Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. | Q53253372 |
| | Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. | Q53578883 |
| | Extracellular Matrix Turnover and Inflammatory Markers Independently Predict Functional Status and Outcome in Chronic Heart Failure | Q57396283 |
| | Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure | Q57951046 |
| | Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure | Q59192141 |
| | Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials | Q59192158 |
| | Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD) | Q59192167 |
| | Myocardial Structure and Function Differ in Systolic and Diastolic Heart Failure | Q62476646 |
| | Negative inotropic effects of cytokines on the heart mediated by nitric oxide | Q68208763 |
| | Elevated circulating levels of tumor necrosis factor in severe chronic heart failure | Q68524243 |
| | Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy | Q71126027 |
| | Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension | Q71606973 |
| | IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells | Q72037726 |
| | High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure | Q73193169 |
| | Plasma cytokine parameters and mortality in patients with chronic heart failure | Q73306471 |
| | Anti-inflammatory cytokine profile in human heart failure: behavior of interleukin-10 in association with tumor necrosis factor-alpha | Q73310597 |
| | Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation | Q73476712 |
| P433 | issue | 5 | |
| P921 | main subject | heart failure | Q181754 |
| | biomarker | Q864574 |
| | chronic heart failure | Q11829287 |
| P304 | page(s) | 513-523 | |
| P577 | publication date | 2009-10-01 | |
| P1433 | published in | Biomarkers in Medicine | Q20313333 |
| P1476 | title | Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure | |
| P478 | volume | 3 | |